PExA AB announced that it has entered into a research collaboration agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the University of Gothenburg. biomarker discovery, was recently selected Awardee of the Carcinogenic Exposure Meter Quickfire Challenge. The Challenge was launched by Johnson & Johnson Innovation, the Lung Cancer Initiative (LCI) at Johnson & Johnson, and Janssen in an effort to help reduce the tobacco epidemic. As part of the collaboration, Janssen will fund the assessment of clinical PEx-samples to identify biomarker categories that potentially can detect carcinogenic damage resulting from tobacco exposure.